Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics

NORCROSS, Ga., June 21, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a U.S. Patent for "Galacto-Rhamnogalacturonate compositions for the treatment of a number of diseases associated with elevated inducible nitric … [Read more...]

The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement

BAR HARBOR, Maine and SANTA CLARA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience (CrownBio), a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), and The Jackson Laboratory (JAX) today announced an agreement to improve the development and accessibility of innovative research models and pre-clinical services to the global biomedical … [Read more...]

Adverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chief Medical Officer

MENLO PARK, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today the appointment of Athena Countouriotis, M.D. as senior vice president and chief medical officer. Dr. Countouriotis will be responsible for … [Read more...]

Yield10 Bioscience CEO Dr. Oliver Peoples to Present at BIO 2017

WOBURN, Mass., June 20, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) announced that CEO Oliver Peoples, Ph.D., will be presenting today at BIO 2017 on a panel entitled: Unpredictable Weather:  How biology-based ag innovations are helping society both mitigate the causes of climate change, and adapt to the impacts as they occur.  This panel is taking place … [Read more...]